Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 12, 2003 - Issue 7
Submit an article Journal homepage
56
Views
10
CrossRef citations to date
0
Altmetric
Review

Novel biological immunotherapies for psoriasis

Jean Kanitakis Department of Dermatology and INSERM U346, Ed. Herriot Hospital (Pav. R), 69437 Lyon cx 03, France. [email protected]
,
Agripina Cristina Butnaru Department of Dermatology and INSERM U346, Ed. Herriot Hospital (Pav. R), 69437 Lyon cx 03, France. [email protected]
&
Alain Claudy Department of Dermatology and INSERM U346, Ed. Herriot Hospital (Pav. R), 69437 Lyon cx 03, France. [email protected]
Pages 1111-1121 | Published online: 02 Mar 2005

Bibliography

  • CHRISTOPHERS E: Psoriasis - epidemiology and clinical spectrum. Clin. Exp. Dermatel (2001) 26:314–320.
  • BOS J, DE PIE MA: The pathogenesis of psoriasis: immunological facts and speculations. Immune] Today (1999) 20:40–46.
  • PRINZ J: Psoriasis vulgaris - a sterile antibacterial skin reaction mediated by cross-reative T cells? An immunological view of the pathophysiology of psoriasis. Clin. Exp. Dermatel (2001) 26:326–332.
  • ASADULLAH K, VOLK HD, STERRY W: Novel immunotherapies for psoriasis. Trends Immune]. (2002) 23:47–53.
  • •Overview discussing the pathogenetic mechanisms of psoriasis and the rationale for using novel immunotherapies for this disease.
  • DISEPIO D, CHANDRARATNA R: New drugs in the treatment of psoriasis. Expert Opin. Investig. Drugs (2000) 9:79–93.
  • GOTTLIEB A, BOS J: Recombinantly engineered human proteins: transforming the treatment of psoriasis. Clin. Immune] (2002) 105:105–116.
  • KIRBY B, GRIFFITHS C: Novel immune-based therapies for psoriasis. Br. Dermatel (2002) 146:546–551.
  • KRUGER J: The immunologic basis for the treatment of psoriasis with new biologic agents.' Am. Acad Dermatel (2002) 46:1–23.
  • ••Comprehensive overview of theimmunological mechanisms underlying psoriasis and discussing the potential targets for novel biologicals.
  • LEBWOHL M: Psoriasis. Lancet (2003) 361:1197–1204.
  • •A general, up-to-date review on psoriasis.
  • MEHRABI D, DICARLO J, SOON S, MCCALL C: Advances in the management of psoriasis: monoclonal antibody therapies. Int. J. Dermatel (2002) 41:827–835.
  • SINGRI P, WEST D, GORDON K: Biologic therapy for psoriasis: the new therapeutic frontier. Arch. Dermatel (2002) 138:657–663.
  • WILLIAMS J, GRIFFITHS C: Cytokineblocking agents in dermatology. Clin. Exp. Dermatel (2002) 27:585–590.
  • WEINSHENKER B, BASS B, EBERS G, RICE G: Remission of psoriatic lesions with muromonab-CD3 (orthoclone OKT3) treatment. Am. Acad. Dermatel (1989) 20:1132–1133.
  • MOREL P, REVILLARD P, NICOLAS JFet al: Anti-CD4 monoclonal antibody therapy in severe psoriasis. I Autoimmunity (1992) 5:465–477.
  • NICOLAS JF, CHAMCHICK N, THIVOLET J et al.: CD4 antibody treatment of severe psoriasis. Lancet (1991) 338:321.
  • •First observation of the efficacy of anti-CD4 antibodies for the treatment of psoriasis.
  • PRINZ J, BRAUN-FALCO 0, MEURER M et al.: Chimaeric CD4 monoclonal antibody in treatment of generalized pustular psoriasis. Lancet (1991) 338:320–321.
  • •First observation of the efficacy of anti-CD4 antibodies for the treatment of psoriasis.
  • RIZOVA H, NICOLAS JF, MOREL P et al.: The effect of anti-CD4 monoclonal antibody treatment on immunopathological changes in psoriatic skin. Dermatel Sci. (1994) 7:1–13.
  • BACHELEZ H, FLAGEUL B, DUBERTRET L et al.: Treatment of recalcitrant plaque psoriasis with a humanised non-depleting antibody to CD4. Auteimmunity (1998) 11:53–62.
  • GOTTLIEB A, LEBWOHL M, SHIRIN S et al.: Anti-CD4 monoclonal antibody treatment dose of moderate to severe psoriasis vulgaris: results of a pilot, multicenter, multiple-dose, placebo- controlled study. " Am. Acad. Dermatol (2000) 43:595–604.
  • DEDRICK RL, WALICKE P, GAROVOY M: Anti-adhesion antibodies efalizumab, a humanized anti-CD1 la monoclonal antibody. Transpl. Immunol (2002) 9:181–186.
  • GOTTLIEB A, KRUEGER J, BRIGHT R et al.: Effects of administration of a single dose of a humanized monoclonal antibody to CD1 la on the immunobiology and clinical activity of psoriasis. J Am. Acad. Dermatol (2000) 42:428–435.
  • PAPP K, BISSONNETTE R, KRUEGER J et al.: The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody. I Am. Acad. Dermatol (2001) 45:665–674.
  • •Double-blind, placebo-controlled, Phase II multi-centre study showing the efficacy of intravenous efalizumab for the treatment of psoriasis.
  • GOTTLIEB A, KRUEGER J, WITTKOWSKI K, DEDRICK R, WALICKE P, GAROVOY M: Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody. Arch. Dermatol (2002) 138:591–600.
  • •Open-label multicentre study showing the beneficial clinical and irnmunobiological effects of intravenous efalizumab in patients with psoriasis.
  • GOTTLIEB A, MILLER J, CHAUDHARI U et al.: Clinical and histological effects of subcutaneously administered anti-CD1la (hull 24) in patients with psoriasis. J Invest. Dermatol (2000) 114:840 (Abstract).
  • GORDON K, LEONARDI C, TYRING S et al: Efalizumab (anti-CD1 la) is safe and effective in the treatment of psoriasis: pooled results of the 12-week first treatment period from two Phase III trials. J Invest. Dermatol (2002) 119:242 (Abstract).
  • KRUEGER J, WALTERS I, MIYAZAWA M et al.: Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis. J Am. Acad. Dermatol (2000) 43:448–458.
  • WOHLRAB J, FISCHER M, TAUBE KM, MARSCH WC: Treatment of recalcitrant psoriasis with daclizumab. Br. J Dermatol (2001) 144:209–210.
  • MROWIETZ U, ZHU K, CHRISTOPHERS E: Treatment of severe psoriasis with anti-CD25 monoclonal antibodies. Arch. Dermatol (2000) 136:675–676.
  • OWEN C, HARRISON P: Successful treatment of severe generalized psoriasis with basiliximab, an interleukin-2 receptor monoclonal antibody. Clin. Exp. Dermatol (2000) 25:195–197.
  • SALIM A, EMERSON R, DALZIEL K: Successful treatment of severe generalized pustular psoriasis with basiliximab (interleukin 2-receptor blocker). Br. J Dermatol (2000) 143:1121–1122.
  • GOTTLIEB A, GILLEAUDEAU P, JOHNSON R et al.: Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat. Med. (1995) 1:442–447.
  • BAGEL J, GARLAND W, BENEMAN D et al.: Administration of DAB389 to patients with recalcitrant psoriasis: a double-blind, Phase II multicenter trial. J. Am. Acad. Dermatol (1998) 38:938–944.
  • MARTIN A, GUTIERREZ E, MUGLIA J et al.: A multicenter dose-escalation trial with denileukin diftitox (ONTAK, DAB389 IL-2) in patients with severe psoriasis. J Am. Acad. Dermatol (2001) 45:871–881.
  • DA SILVA A, BRICKELMAIER M, MAJEAU G et al.: Alefacept, an immunomodulatory recombinant LFA-3/ IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2+ cells." Immunol (2002) 168:4462–4471.
  • MAGILAVY D, MANT T, NORMAN P et al.: Pharmacodynamic effects of LFA3-TIP (Amevive) in patients with chronic plaque psoriasis: selective modulation of CD45R0+ lymphocytes. J. Invest. Dermatol (1999) 112:609 (Abstract).
  • ELLIS C, KRUEGER G: Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl. J. Med. (2001) 345:248–255.
  • ••Multi-centre, randomised, placebo-controlled study demonstrating the efficacy of intravenous alefacept for the treatment of psoriasis.
  • ELLIS C, MORDIN M, ADLER E: Effects of alefacept on health-related quality of life in patients with psoriasis: results from a randomized, placebo-controlled Phase II trial. Am. J. Clin. Dermatol (2003) 4:131–139.
  • CHRISTOPHERS E, BOURCIER M, GRIFFITHS C: Study design and demographics of a randomised, double-blind, placebo-controlled Phase III dose-comparison study to evaluate weekly intramuscular administration of alefacept in chronic plaque psoriasis. J Eur: Acad. Dermatol Venereol (2001) 15\(Suppl. 2):248 (Abstract).
  • KRUGER J: Selective targeting of T cell subsets: focus on alefacept - a remittive therapy for psoriasis. Expert Opin. Biol. Ther: (2002) 2:431–441.
  • •Detailed review on the use of alefacept for the treatment of psoriasis.
  • KRUEGER G, PAPP K, STOUGH D, LOVEN K, GULLIVER W, ELLIS C: A randomized, double-blind, placebo-controlled Phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am. Acad. Dermatol (2002) 47:821–833.
  • •Phase III, randomised, placebo-controlled study demonstrating the efficacy of two courses of intravenous alefacept for the treatment of psoriasis.
  • ORTONNE JP, KHEMIS A, KOO J: Combination therapy with alefacept and ultraviolet B light for treatment of psoriasis. Eur. Acad. Dermatol Venereol (2003) 17\(Suppl. 1):51–52 (Abstract).
  • KRAAN M, VAN KUIJK A, DINANT H et al.: Alefacept treatment in psoriatic arthritis: reduction of the effector T-cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritic Rheum. (2002) 46:2776–2784.
  • •Open-label explorative study suggesting the efficacy of alefacept for the treatment of psoriatic arthritis.
  • LEBWOHL M, GORDON K, LOWE N, LANGLEY R, GRIFFITHS C, CHRISTOPHERS E: Safety profile of alefacept: pooled results of placebo-controlled trials. Ann. Dermatol Venereol (2002) 129:1S761 (Abstract).
  • LOWE N, GRIFFITHS C, GOTTLIEB A: Selective reductions in memory-effector (CD45R0+) T cells by alefacept are related to clinical improvement in psoriasis. J Invest. Dermatol (2002) 119:345 (Abstract).
  • ORTONNE JP, LEBWOHL M, GRIFFITHS C: Alefacept-induced decreases in circulating blood lymphocyte counts correlate with clinical response in patients with chronic plaque psoriasis. Euc J.Dermatol. (2003) 13:117–123.
  • LANGLEY R, ROENIGK H, MCCALL C et al.: Phase I results of intravenous MEDI-507, an anti-T cell monoclonal antibody, for the treatment of psoriasis. Invest. Dermatol (2001) 117:817 (Abstract).
  • NAJAFIAN N, SAYEGH M: CTLA4-Ig: a novel immunosuppressive agent. Expert Opin. Investig. Drugs (2000) 9:2149–2157.
  • ABRAMS J, LEBWOHL M, GUZZO C et al.: CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. Clin. Invest. (1999) 103:1243–1252.
  • ABRAMS J, KELLEY S, HAYES E et al.: Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. Exp. Med. (2000) 192:681–694.
  • ••Clinicopathological study showing that theB7-targeted disruption of APC-T-cell interaction induces psoriasis improvement via the blockade of T-cell activation.
  • GOTTLIEB A, LEBWOHL M, TOTORITIS M et al: Clinical and histological response to single-dose treatment of moderate to severe psoriasis with an anti-CD80 monoclonal antibody. J. Am. Acad. Dermatol (2002) 47:692–700.
  • GIROLOMONI G, PASTORE S, ALBANESI C, CAVANI A: Targeting tumor necrosis factor-alpha as a potential therapy in inflammatory skin diseases. Curr: Op. Invest. Drugs (2002) 3:1590–1595.
  • •Review of the usefulness of anti-TNF-a biologicals for the treatment of inflammatory dermatoses (including psoriasis).
  • OH C, DAS K, GOTTLIEB A: Treatmentwith anti-tumor necrosis factor-alpha (TNF-a) monoclonal antibody dramatically decreases the clinical activity of psoriatic lesions. Am. Acad. Dermatol (2000) 42:829–830.
  • CHAUDHARI U, ROMANO P, MULCAHY L et al.: Efficacy and safety of infliximab monotherapy for plaque-type psoriasis. Lancet (2001) 357:1842–1847.
  • ••Randomised, controlled trial showing theefficacy of infliximab as monotherapy for psoriasis.
  • SCHOPF R, AUST H, KNOP J: Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor alpha, infliximab. .1 Am. Acad. DermatoL (2002) 46:886–891.
  • GOTTLIEB A, MASUD S, RAMAMURTHI R et al.: Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris. Am. Acad. Dermatol (2003) 48:68–75.
  • •Study showing the irnmunohistological effects of infliximab on psoriasis lesions.
  • O'QUINN R, MILLER J: The effectiveness of tumor necrosis factor-alpha antibody (infliximab) in treating recalcitrant psoriasis: a report of 2 cases. Arch. Dermatol (2002) 138:644–648.
  • MANGAS DE ARRIBA C, BIELSA I, CARRASCOSA JM, RIBERA M, FERNANDEZ N, FERRANDIZ C: Efficacy of infliximab in a patient with severe psoriasis. Ann. Dermatol Venereol (2002) 129:1S763 (Abstract).
  • STEVENS M, LEE W, MAKAROWSKI W et al.: Infliximab in the treatment of psoriatic arthritis and psoriasis. Ann. Dermatol Venereol (2002) 129:1S768 (Abstract).
  • OGILVIE A, ANTONI C, DECHANT C et al.: Treatment of psoriatic arthritis with anti-tumor necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br. Dermatol (2001) 144:587–589.
  • BIANCHI L, PARO VIDOLIN A, NETO I, ESO-POSITO M, GIUNTA A, CHIMENTI S: Efficacy and safety of infliximab in the treatment of severe plaque or arthropathic psoriasis: preliminatry observations. Ann. Dermatol Venereol (2002) 129:1S751 (Abstract).
  • KIRBY B, GRIFFITHS C: Infliximab combination therapy for psoriasis. Ann. Dermatol Venereol (2002) 129:1S759 (Abstract).
  • KIRBY B, MARSLAND A, CARMICHAEL A, GRIFFITHS C: Successful treatment of severe recalcitrant psoriasis with combination infliximab and methotrexate. Clin. Exp. Dermatol (2001) 26:27–29.
  • TAN MH, GORDON M, LEBWOHL 0, GEORGE J, LEBWOHL M: Improvement of pyoderma gangrenosum and psoriasis associated with Crohn disease with anti- tumor necrosis factor a monoclonal antibody. Arch. DermatoL (2001) 137:930–933.
  • GOTTLIEB A, ROMANO P, CHAUDHARI U, BAKER D, LI S: Infliximab prevents relapse of moderate to severe psoriasis in responding patients. Ann. Dermatol Venereol (2000) 129:1S757 (Abstract).
  • ELEWSKI B: Infliximab for the treatment of severe pustular psoriasis.' Am. Acad. Dermatol (2002) 47:796–797.
  • NEWLAND M, WEINSTEIN A, KERDEL F: Rapid response to infliximab in severe pustular psoriasis, von Zumbusch type. Int. 1 Dermatol (2002) 41:449–452.
  • ANTONI C, DECHANT C, HANNS-MARTIN LORENZ P et al.: Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. Arthritic Rheum. (2002) 47:506–512.
  • •Open clinical trial showing the efficacy of infliximab for the treatment of psoriatic arthritis.
  • ANTONI C, MANGER B: Infliximab for psoriasis and psoriatic arthritis. Clin. Exp. Rheumatol (2002) 20\(Suppl. 28):5122–125.
  • CAUZA E, SPAK M, CAUZA K, HANNUSCH-ENSERER U, DUNKY A, WAGNER E: Treatment of psoriatic arthritis and psoriasis vulgaris with the tumor necrosis factor inhibitor infliximab. Rheumatol Int. (2002) 22:227–232.
  • •Open clinical trial showing the efficacy of infliximab for the treatment of cutaneous and joint lesions of psoriasis.
  • VERGARA G, SILVESTRE JF, BETTLOCH I, ALBARES MP, PASCUAL JC: Cutaneous drug eruption to infliximab: report of 4 cases with an interface dermatitis pattern. Arch. Dermatol (2002) 138:1258–1259.
  • KEANE J, GERSHON S, WISE RP et al: Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N. EngL J. Med. (2001) 345:1098–1104.
  • SLIFMAN N, GERSHON S, LEE J, EDWARDS E, BRAUN M: Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritic Rheum. (2003) 48:319–324.
  • MACHOLD K, SMOLEN J: Adalimumab - a new TNF-alpha antibody for treatment of inflammatory joint disease. Expert Opin. Biol. Ther. (2003) 3:351–560.
  • MEASE PJ, GOFFE BS, METZ J, VANDERSTOEP A, FINCK B, BURGE DJ: Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet (2000) 356:385–390.
  • ••Randomised double-blind, placebo-controlled trial showing the efficacy of etanercept for the treatment of psoriatic arthritis and psoriasis.
  • MEASE P: Psoriatic arthritis: the role of TNF inhibition and the effect of its inhibition with etanercept. Clin. Exp. Rheumatol (2002) 20\(Suppl. 28):S116–121.
  • KRUEGER G, LEBWOHL M, GOTTLIEB A, MEASE P, BURGE D: Etanercept improves psoriasis in patients with psoriatic arthritis: results of a Phase III multicentric clinical trial. Ann. Dermatol Venereol (2002) 129:1S760 (Abstract).
  • GOTTLIEB A, MATHESON R LOWE N, ZITNIK R: Efficacy of Enbrel in patients with psoriasis. Invest. Dermatol (2002) 119:234 (Abstract).
  • LOWE N, LEBSACK M, WANKE L: Psoriasis patients show improved quality of life when treated with etanercept. Ann. Dermatol Venereol (2002) 129:1S762 (Abstract).
  • GASPARI A, GOTTLIEB A, KANG S, GORDON K, FENG A, ZITNIK R: Enbrel improves the clinical and pathological features of psoriasis. Invest. Dermatol (2002) 119:236 (Abstract).
  • WOLLINA U, KONRAD H: Treatment of recalcitrant psoriatic arthritis with anti-tumor necrosis factor-alpha antibody. Ear: Acad. Dermatol Venereol (2002) 16:127–129.
  • IYER S, YAMAUCHI P, LOWE NJ: Etanercept for severe psoriasis and psoriatic arthritis: observations on combination therapy. Br. Dermatol (2002) 146:118–121.
  • KAMARASHEV J, LOR P, FORSTER A,HEINZERLING L, BURG G, NESTLE F: Generalised pustular psoriasis induced by cyclosporine A withdrawal responding to the tumor necrosis factor alpha inhibitor etanercept. Dermatology (2002) 205:213–216.
  • ZELTSER R VALLE L, TANCK C, HOLYST M, RITCHLIN C, GASPARI A: A recombinant tumor necrosis alpha receptor:Fc fusion protein. Clinical, histological and immunophenotypical characteristics of injection site reactions associated with etanercept. Arch. Dermatol (2001) 137:893–899.
  • VAN OOSTEN BW, BARKHOF F, TRUYEN L et al.: Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology (1996) 47:1531.
  • RUTGEERTS P, LEMMENS L, VAN ASSCHE G, NOMAN M, BORGHINI-FUHRER I, GOEDKOOP R: Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open-label, pilot study. Ailment. Pharmacol Ther: (2003) 17:185–192.
  • LOHNER M, KRUEGER J, GOTTLIEB A et al.: Clinical trials of a fully human anti-IL-8 antibody for the treatment of psoriasis. Br. DermatoL (1999) 141:989 (Abstract).
  • HOROWITZ M, KRUEGER J, BELL G, HUANG S, WYERS M, CHEN F: ABX-IL8 in the treatment of psoriasis: clinical results. Invest. Dermatol (2002) 119:239 (Abstract).
  • KRUEGER J, TABRIZI M, HUANG S et al.: Pharmacokinetics and pharmacodynamics of ABX-1L8 in patients with psoriasis. Invest. Dermatol (2002) 119:239 (Abstract).
  • GHORESCHI K, THOMAS P, BREIT S et al.: Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat. Med. (2003) 9:40–46.
  • ••Prospective study showing the efficacy ofrecombinant human IL-4 for psoriasis via TH2 differentiation in CD4+ T cells.
  • ASADULLAH K, STERRY W, STEPHANEK K et al: IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach. Clin. Invest. (1998) 101:783–794.
  • ASADULLAH K, DOCKE W, EBELING M et al.: Interleuldn 10 treatment of psoriasis: clinical results of a Phase II trial. Arch. Dermatol (1999) 135:187–192.
  • REICH K, GARBE C, BLASCHKE V et al.: Response of psoriasis to interleukin 10 is associated with suppression of cutaneous Type 1 inflammation, downregulation of the epidermal interleukin-8/CXCR2 pathway and normalization of keratinocyte maturation. Invest. Dermatol (2001) 116:319–329.
  • ASADULLAH K, FRIEDRICH M, HANNEKEN S et al.: Effects of systemic interleukin-10 therapy on psoriatic skin lesions: histologic, immunohistologic, and molecular biology findings. Invest. Dermatol (2001) 116:721–727.
  • FRIEDRICH M, DOCKE WD, KLEIN Aet al.: Immunomodulation by interleukin-10 therapy decreases the incidence of relapse and prolongs the relapse-free interval in psoriasis. Invest. Dermatol (2002) 118:672–677.
  • KIMBALL AB, KAWAMURA T, TEJURA K et al.: Clinical and immunologic assessment of patients with psoriasis in a randomized, double-blind, placebo-controlled trial using recombinant human interleukin 10. Arch. Dermatol (2002) 138:1341–1346.
  • TREPICCHIO W, OZAWA M, WALTERS I et al.: Interleukin 11 therapy selectively downregulates Type 1 cytokine proinflammatory pathways in psoriatic lesions. Clin. Invest. (1999) 104:1527–1537.

Website

  • http://www.psoriasis.org National Psoriasis Foundation website. Affiliation

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.